UniProt P49761 · PDB · AlphaFold · Substrate: MBP · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 43.5% | 56.5% | 87.22 | 0.555 |
| 2 | Ceritinib | 25.8% | 74.2% | 95.44 | 0.618 |
| 3 | Dabrafenib | 20.5% | 79.5% | 94.74 | 0.633 |
| 4 | Dacomitinib | 19.9% | 80.1% | 97.99 | 0.664 |
| 5 | Baricitinib | 19.3% | 80.7% | 97.99 | 0.616 |
| 6 | Ribociclib | 18.8% | 81.2% | 99.25 | 0.729 |
| 7 | Ibrutinib | 18.1% | 81.9% | 94.74 | 0.723 |
| 8 | Defactinib | 17.4% | 82.6% | 92.68 | 0.450 |
| 9 | Imatinib | 16.0% | 84.0% | 99.00 | 0.718 |
| 10 | Osimertinib | 15.4% | 84.6% | 97.24 | 0.733 |
| 11 | Pazopanib | 14.4% | 85.6% | 97.49 | 0.672 |
| 12 | Capivasertib | 13.7% | 86.3% | 96.48 | 0.644 |
| 13 | Lorlatinib | 13.1% | 86.9% | 97.24 | 0.694 |
| 14 | Encorafenib | 12.9% | 87.1% | 98.50 | 0.755 |
| 15 | Tofacitinib | 12.4% | 87.6% | 99.25 | 0.684 |
| 16 | Brigatinib | 12.4% | 87.6% | 82.96 | 0.513 |
| 17 | Ruxolitinib | 11.8% | 88.2% | 98.25 | 0.592 |
| 18 | Fostamatinib | 11.6% | 88.4% | 96.74 | 0.613 |
| 19 | Binimetinib | 10.9% | 89.1% | 100.00 | 0.689 |
| 20 | Repotrectinib | 10.9% | 89.1% | 84.21 | 0.608 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.24
- Epithelial log2(TPM+1): 5.26
- Fold change: -0.02
- Status: No significant change
Selectivity landscape vs inhibition on CLK3
Each point is one of the 92 approved drugs; color = inhibition % on CLK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…